FDA lifts hold on Halozyme pancreatic cancer study; shares leap
This article was originally published in Scrip
Executive Summary
Shares of Halozyme leaped 13%, or $1.05, in after-hours trading on 4 June after the company revealed the FDA had lifted the clinical hold on the firm’s Phase II trial of PEGPH20, a pegylated form of recombinant human hyaluronidase, in patients with pancreatic cancer.